ArticleJournal of Cancer2017
Efficacy of Second-line Tyrosine Kinase Inhibitors in the Treatment of Metastatic Advanced Non-small-cell Lung Cancer Harboring Exon 19 and 21 EGFR Mutations.
Article in Journal of Cancer, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed, 11 citations in OpenAlex.
- Prediction of EGFR mutation status and mutation sites in lung cancer based on radiomics and deep learning.Journal of thoracic disease · 2025Article
- Matching-adjusted indirect comparison of selpercatinib and pralsetinib inFuture oncology (London, England) · 2025Article
- Differential clinicopathological features, treatments and outcomes in patients with Exon 19 deletion and Exon 21 L858R EGFR mutation-positive adenocarcinoma non-small-cell lung cancer.BMJ open respiratory research · 2023Review
- Transformation to small-cell lung cancer following treatment with icotinib in a patient with lung adenocarcinoma.Oncology letters · 2018Article
- The impact of EGFR mutations on the incidence and survival of stages I to III NSCLC patients with subsequent brain metastasis.PloS one · 2018Article
- Survival difference betweenChinese journal of cancer research = Chung-kuo yen cheng yen chiu · 2017Article
- Validation of the graded prognostic assessment for lung cancer with brain metastases using molecular markers (lung-molGPA).Radiation oncology (London, England) · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.